Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 1
2010 1
2011 1
2012 1
2013 4
2014 2
2015 1
2016 1
2017 2
2018 4
2019 6
2020 4
2021 4
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
Tassone P, Di Martino MT, Arbitrio M, Fiorillo L, Staropoli N, Ciliberto D, Cordua A, Scionti F, Bertucci B, Salvino A, Lopreiato M, Thunarf F, Cuomo O, Zito MC, De Fina MR, Brescia A, Gualtieri S, Riillo C, Manti F, Caracciolo D, Barbieri V, Di Paola ED, Di Francesco AE, Tagliaferri P. Tassone P, et al. Among authors: barbieri v. J Hematol Oncol. 2023 Jun 26;16(1):68. doi: 10.1186/s13045-023-01468-8. J Hematol Oncol. 2023. PMID: 37365583 Free PMC article. Clinical Trial.
Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology.
Minici R, Siciliano MA, Ammendola M, Santoro RC, Barbieri V, Ranieri G, Laganà D. Minici R, et al. Among authors: barbieri v. Cancers (Basel). 2022 Dec 30;15(1):257. doi: 10.3390/cancers15010257. Cancers (Basel). 2022. PMID: 36612251 Free PMC article.
Long-term proliferation of immature hypoxia-dependent JMML cells supported by a 3D in vitro system.
Cani A, Tretti Parenzan C, Frasson C, Rampazzo E, Scarparo P, Francescato S, Caicci F, Barbieri V, Rosato A, Cesaro S, Zecca M, Micalizzi C, Sainati L, Pigazzi M, Biffi A, Buldini B, Locatelli F, Persano L, Masetti R, Te Kronnie G, Bresolin S. Cani A, et al. Among authors: barbieri v. Blood Adv. 2023 Apr 25;7(8):1513-1524. doi: 10.1182/bloodadvances.2021006746. Blood Adv. 2023. PMID: 36053787 Free PMC article.
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics.
Staropoli N, Arbitrio M, Salvino A, Scionti F, Ciliberto D, Ingargiola R, Labanca C, Agapito G, Iuliano E, Barbieri V, Cucè M, Zuccalà V, Cannataro M, Tassone P, Tagliaferri P. Staropoli N, et al. Among authors: barbieri v. Biomedicines. 2022 May 23;10(5):1210. doi: 10.3390/biomedicines10051210. Biomedicines. 2022. PMID: 35625946 Free PMC article.
Corrigendum to "Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma" [Eur J Canc 157 (2021) 250-258].
Baggi A, Quaglino P, Rubatto M, Depenni R, Guida M, Ascierto PA, Trojaniello C, Queirolo P, Saponara M, Peris K, Spagnolo F, Bianchi L, De Galitiis F, Potenza MC, Proietti I, Marconcini R, Botticelli A, Barbieri V, Licitra L, Alfieri S, Ficorella C, Cortellini A, Fargnoli MC, Troiani T, Tondulli L, Zamparini M, Bossi P. Baggi A, et al. Among authors: barbieri v. Eur J Cancer. 2022 May;166:309-310. doi: 10.1016/j.ejca.2022.02.027. Epub 2022 Mar 24. Eur J Cancer. 2022. PMID: 35341663 Free article. No abstract available.
Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistance.
Romani P, Nirchio N, Arboit M, Barbieri V, Tosi A, Michielin F, Shibuya S, Benoist T, Wu D, Hindmarch CCT, Giomo M, Urciuolo A, Giamogante F, Roveri A, Chakravarty P, Montagner M, Calì T, Elvassore N, Archer SL, De Coppi P, Rosato A, Martello G, Dupont S. Romani P, et al. Among authors: barbieri v. Nat Cell Biol. 2022 Feb;24(2):168-180. doi: 10.1038/s41556-022-00843-w. Epub 2022 Feb 14. Nat Cell Biol. 2022. PMID: 35165418 Free PMC article.
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report.
d'Apolito M, Spagnuolo R, Siciliano MA, Barbieri V, Cosco C, Fiorillo L, Cuomo O, Zuccalà V, Correale P, Pensabene L, Rossi M, Doldo P, Tassone P, Tagliaferri P. d'Apolito M, et al. Among authors: barbieri v. Ther Adv Chronic Dis. 2022 Jan 13;13:20406223211063024. doi: 10.1177/20406223211063024. eCollection 2022. Ther Adv Chronic Dis. 2022. PMID: 35070249 Free PMC article.
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis.
Nardone V, Giannicola R, Giannarelli D, Saladino RE, Azzarello D, Romeo C, Bianco G, Rizzo MR, Di Meo I, Nesci A, Pastina P, Falzea AC, Caracciolo D, Reginelli A, Caraglia M, Luce A, Mutti L, Giordano A, Cappabianca S, Pirtoli L, Barbieri V, Tassone P, Tagliaferri P, Correale P. Nardone V, et al. Among authors: barbieri v. Life (Basel). 2021 Nov 15;11(11):1235. doi: 10.3390/life11111235. Life (Basel). 2021. PMID: 34833111 Free PMC article.
38 results